David Delarbre

Dr. David Delarbre

Hôpital d'Instruction des Armées Sainte-Anne, Toulon, Provence-Alpes-Côte d’Azur, France
+1

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
LBLaurys BOUDIN
Laurys BOUDIN
JMJean-Baptiste Morvan
Jean-Baptiste Morvan
Juliette THARIATJuliette THARIAT
Juliette THARIAT
DMDenis Métivier
Denis Métivier
PMPierre Yves Marcy
Pierre Yves Marcy
DDDavid Delarbre
David Delarbre
Anaplastic thyroid carcinoma (ATC) are highly aggressive malignant tumors with poor overall prognosis despite multimodal therapy. As ATC are extremely rare, no randomized controlled study has been published for metastatic disease. Thyrosine kinase inhibitors, especially lenvatinib and immune checkpoint inhibitors such as pembrolizumab, are emerging drugs for ATC. Few studies have reported the efficacity of pembrolizumab and lenvatinib association, resulting in its frequent off-label use. In this review, we discuss rationale efficacy and safety evidence for the association of lenvatinib and pembrolizumab in ATC. First, we discuss preclinical rationale for pembrolizumab monotherapy, lenvatinib monotherapy and synergistic action of pembrolizumab and lenvatinib in the metastatic setting. We also discuss clinical evidence for immunotherapy and pembrolizumab in ATC through the analysis of studies evaluating immunotherapy, lenvatinib and pembrolizumab lenvatinib association in ATC. In addition, we discuss the safety of this association and potential predictive biomarkers of efficiency.

26 November 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
JMJean-Baptiste Morvan
Jean-Baptiste Morvan
LBLaurys BOUDIN
Laurys BOUDIN
DMDenis Métivier
Denis Métivier
DDDavid Delarbre
David Delarbre
EBEdouard Bouquillon
Edouard Bouquillon
PMPierre Yves Marcy
Pierre Yves Marcy
Internal jugular vein tumor thrombus is an extremely rare condition in thyroid carcinoma, but it does exist. Correlated with greater aggressiveness with a higher incidence of distant metastases at diagnosis and a higher recurrence rate, this important prognostic element should be systematically investigated by ultrasound operators in all patients presenting with thyroid carcinoma. The patient’s follow-up must be careful. This can be a trap that surgeons must look for in their preoperative checklist. We report the case of a 58-year-old woman with an IJV thrombus associated with multiple bone metastases. She underwent successful surgical treatment, and postoperative pathology showed a poorly differentiated follicular carcinoma of the thyroid and a tumor thrombus in the internal jugular vein.

1 November 2021 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
DDDavid Delarbre
David Delarbre
LGL. Gan
L. Gan
CAC. Antoine
C. Antoine
EPE. Poisnel
E. Poisnel
ACA. Cambon
A. Cambon
GDG. Defuentes
G. Defuentes

8 September 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
OBOlivier Bylicki
Olivier Bylicki
DDDavid Delarbre
David Delarbre
AMAurélie Mayet
Aurélie Mayet
AFAudrey Ferrier
Audrey Ferrier
APAnne Perisse
Anne Perisse
JTJean-Nicolas Tournier
Jean-Nicolas Tournier
A better understanding of the immune response against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is critical to predict its dynamics within the general population and its impact on the vaccination strategy. This study assessed the persistence of neutralizing antibody (Nab) activity and SARS-CoV-2 serology in serum samples of mild and asymptomatic patients 9 months post symptom onset (PSO) in a primary care context among immunocompetent adults. A longitudinal cohort of crew members (CMs) exposed to coronavirus disease 2019 (COVID-19) during an outbreak of SARS-CoV-2 on the French aircraft carrier ‘Charles de Gaulle’ in April 2020 was created. CMs infected with COVID-19 and with positive serology at the end of quarantine were tested 9 months PSO. Samples were collected 18 and 280 days PSO. For each patient, both serology and serum viral neutralizing activity were performed. In total, 86 CMs were analysed. Samples were collected 18 and 280 days PSO. The seroconversion rates were 100% and 93% (82/86) at 18 and 280 days PSO, respectively, and 72.7% of patients exhibited persistent Nab activity at 9 months, regardless of disease severity. Nab activity persists for up to 9 months following asymptomatic/mild COVID-19 among young adults, regardless of serological results.

22 June 2024 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
DDDavid Delarbre
David Delarbre
PLPhilippe Lavrard
Philippe Lavrard
AEAntoine Elias
Antoine Elias
VBVincent Bossi
Vincent Bossi
IKIdir Kacel
Idir Kacel
PFPierre-Edouard Fournier
Pierre-Edouard Fournier

31 October 2023 in Enfermedades Infecciosas y Microbiologia Clinica (English Ed.)
Verified
Journal Article
Closed access
DDDavid Delarbre
David Delarbre
CJCamille Junca-Laplace
Camille Junca-Laplace
MOMarie-Pierre Otto
Marie-Pierre Otto
CACarole Antoine
Carole Antoine
GDGilles Defuentes
Gilles Defuentes